BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells
about
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesPPARalpha and AP-2alpha regulate bombesin receptor subtype 3 expression in ozone-stressed bronchial epithelial cellsInsights into bombesin receptors and ligands: Highlighting recent advancesIsolation, identification and biological activity of gastrin-releasing peptide 1-46 (oGRP 1-46), the primary GRP gene-derived peptide product of the pregnant ovine endometrium.Bombesin receptor subtype 3 as a potential target for obesity and diabetes.Novel chiral-diazepines function as specific, selective receptor agonists with variable coupling and species variability in human, mouse and rat BRS-3 receptor cells.Signal transduction of bombesin-induced circular smooth muscle cell contraction in cat esophagus.Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4).Bombesin and [Leu8]phyllolitorin promote fetal mouse lung branching morphogenesis via a receptor-mediated mechanismBombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.Effect of bombesin receptor subtype-3 and its synthetic agonist on signaling, glucose transport and metabolism in myocytes from patients with obesity and type 2 diabetes.ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.Gastrin releasing peptide receptor expression is decreased in patients with Crohn's disease but not in ulcerative colitis.Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Selective reconstitution of gastrin-releasing peptide receptor with G alpha qReduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.Loss of bombesin-induced feeding suppression in gastrin-releasing peptide receptor-deficient mice.High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa.The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.Morphological and physiological properties of serotonergic neurons in dissociated cultures from the postnatal rat dorsal raphe nucleus.Factors contributing to obesity in bombesin receptor subtype-3-deficient miceTargeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa.Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.Pharmacological characterization of a selective agonist for bombesin receptor subtype-3.Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.Regulation of body temperature and brown adipose tissue thermogenesis by bombesin receptor subtype-3.The Gastrin-Releasing Peptide Receptor (GRPR) in the Spinal Cord as a Novel Pharmacological TargetA human GRPr-transfected Ace-1 canine prostate cancer model in mice.Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation.Identification and functional characterization of hemorphins VV-H-7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3.Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patientsMolecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.Molecular cloning and characterization of avian bombesin-like peptide receptors: new tools for investigating molecular basis for ligand selectivity.Bombesin-like receptor 3 (Brs3) expression in glutamatergic, but not GABAergic, neurons is required for regulation of energy metabolism.A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.
P2860
Q24643524-4CE9EE47-DB3E-4F32-924D-BDCECAB4BB27Q24669586-27DA3018-6704-4A35-8E6A-33F1DC55FB85Q28081153-E24750F3-9C58-40DC-832E-922325990BD3Q30925323-38CAC711-D522-48F1-A74B-EE85CD50EEF4Q33637115-BF5C2270-BCE0-46EF-B90A-94B4581D8BBAQ33771938-D6A3C9DE-A9CB-4898-AB86-F3246D9FF2D9Q33867182-D2E95BD5-65E0-4386-B637-89757F28B8FCQ34001098-94D071CD-E972-4AF4-BAC3-9CF32DEEC323Q34202759-DE03941D-F45E-4896-89F5-8A0917422619Q34325472-AB34913F-C86A-4B2B-B4F3-6338DB09181EQ35154082-46A9052A-D9AD-4BFA-9A56-4841701E17FEQ35154092-AA702FE3-C360-488A-A1E9-49C64EA0FBE9Q35167907-167881DA-896A-456F-ACEA-64A174F35E6DQ35417648-72C1779B-55A9-409B-8F44-989C46F23E7BQ35587983-0C3BABD6-FCF1-47F9-AAAF-37E8B9C60500Q35959684-B14F6073-9FF4-4507-9C7A-C80B17340A6EQ35961860-6F8CF51D-1C5D-4C88-8103-64224B1C6887Q35966914-9E06B8E6-6AB7-472D-9952-9366D73B6B85Q35982711-E233BC94-7EAC-4181-83A4-B0B03E1E9667Q36080872-023ED245-FF52-4FF0-A9DD-70CBCB986105Q36208460-C9BA2D7D-E19E-43E5-BB1B-14258A99C91DQ36447473-B949E074-DE5E-4F93-9B23-7C0048398FE0Q36509779-7D86697A-F864-479B-945E-532B604F4AD3Q36619952-92953273-8334-43E9-A27A-27911941A5B9Q36620745-74BC163E-5F20-4436-839B-564A62999C55Q36994139-0F0B9F56-5A70-4E01-B249-65769E2CBE93Q37354930-20146D3C-17A1-4CB2-9854-61FBA400E33AQ37398035-FAE4C7AE-175D-4972-897F-D40BD4522B73Q37629044-287C0EC5-9E0C-4AC6-A547-01F8186D96C5Q38271570-709A9A0E-17ED-4216-BF01-AA5B4FF40D64Q38789134-A7F0FD06-3A75-4B18-AE20-3E5F30D2F1F5Q39513835-1AFF3E4E-0F2F-49DE-9406-4069BE735302Q40003185-4B51B187-CFA1-48A3-98DF-DBB1FCB222D4Q40337525-D3965E57-8902-4DBD-86D2-D91387EC9043Q40651404-C88CBAFA-6A2C-45E2-8D2E-5F9A57AE2DCEQ42358803-A5D5F48A-AC8B-463E-B8EF-A94F5798AC47Q42365925-52AAD657-AEC0-46C0-8CFD-F8E585CF636DQ43263367-D8B85F01-55D3-40BA-90AA-12289E62B2F4Q47151177-8C13955A-B8EF-46F0-97A0-87CD234305ECQ50149052-C5504953-3EE6-4A8F-8B88-9BC98662EF3B
P2860
BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells
description
1993 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մարտին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artículu científicu espublizáu en 1993
@ast
im März 1993 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1993/03/15)
@sk
vědecký článek publikovaný v roce 1993
@cs
wetenschappelijk artikel (gepubliceerd op 1993/03/15)
@nl
наукова стаття, опублікована в березні 1993
@uk
name
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@ast
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@en
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@nl
type
label
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@ast
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@en
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@nl
prefLabel
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@ast
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@en
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@nl
P2093
P1476
BRS-3: a novel bombesin recept ...... estis and lung carcinoma cells
@en
P2093
Sausville EA
P304
P407
P577
1993-03-01T00:00:00Z